351 related articles for article (PubMed ID: 25755299)
1. Histone Deacetylase Inhibitors (HDACi) Cause the Selective Depletion of Bromodomain Containing Proteins (BCPs).
Mackmull MT; Iskar M; Parca L; Singer S; Bork P; Ori A; Beck M
Mol Cell Proteomics; 2015 May; 14(5):1350-60. PubMed ID: 25755299
[TBL] [Abstract][Full Text] [Related]
2. Using Histone Deacetylase Inhibitors to Analyze the Relevance of HDACs for Translation.
Hutt DM; Roth DM; Marchal C; Bouchecareilh M
Methods Mol Biol; 2017; 1510():77-91. PubMed ID: 27761814
[TBL] [Abstract][Full Text] [Related]
3. Histone deacetylase inhibitors selectively suppress expression of HDAC7.
Dokmanovic M; Perez G; Xu W; Ngo L; Clarke C; Parmigiani RB; Marks PA
Mol Cancer Ther; 2007 Sep; 6(9):2525-34. PubMed ID: 17876049
[TBL] [Abstract][Full Text] [Related]
4. Mass spectrometry and DigiWest technology emphasize protein acetylation profile from Quisinostat-treated HuT78 CTCL cell line.
Méhul B; Perrin A; Grisendi K; Galindo AN; Dayon L; Ménigot C; Rival Y; Voegel JJ
J Proteomics; 2018 Sep; 187():126-143. PubMed ID: 30012418
[TBL] [Abstract][Full Text] [Related]
5. DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines.
LaBonte MJ; Wilson PM; Fazzone W; Groshen S; Lenz HJ; Ladner RD
BMC Med Genomics; 2009 Nov; 2():67. PubMed ID: 19948057
[TBL] [Abstract][Full Text] [Related]
6. Histone deacetylase inhibitors interfere with angiogenesis by decreasing endothelial VEGFR-2 protein half-life in part via a VE-cadherin-dependent mechanism.
Hrgovic I; Doll M; Pinter A; Kaufmann R; Kippenberger S; Meissner M
Exp Dermatol; 2017 Feb; 26(2):194-201. PubMed ID: 27487811
[TBL] [Abstract][Full Text] [Related]
7. Analysis of the genomic response of human prostate cancer cells to histone deacetylase inhibitors.
Kortenhorst MS; Wissing MD; Rodríguez R; Kachhap SK; Jans JJ; Van der Groep P; Verheul HM; Gupta A; Aiyetan PO; van der Wall E; Carducci MA; Van Diest PJ; Marchionni L
Epigenetics; 2013 Sep; 8(9):907-20. PubMed ID: 23880963
[TBL] [Abstract][Full Text] [Related]
8. Differential effects of class I isoform histone deacetylase depletion and enzymatic inhibition by belinostat or valproic acid in HeLa cells.
Dejligbjerg M; Grauslund M; Litman T; Collins L; Qian X; Jeffers M; Lichenstein H; Jensen PB; Sehested M
Mol Cancer; 2008 Sep; 7():70. PubMed ID: 18789133
[TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase (HDAC) inhibitor kinetic rate constants correlate with cellular histone acetylation but not transcription and cell viability.
Lauffer BE; Mintzer R; Fong R; Mukund S; Tam C; Zilberleyb I; Flicke B; Ritscher A; Fedorowicz G; Vallero R; Ortwine DF; Gunzner J; Modrusan Z; Neumann L; Koth CM; Lupardus PJ; Kaminker JS; Heise CE; Steiner P
J Biol Chem; 2013 Sep; 288(37):26926-43. PubMed ID: 23897821
[TBL] [Abstract][Full Text] [Related]
10. Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy.
Singh AK; Bishayee A; Pandey AK
Nutrients; 2018 Jun; 10(6):. PubMed ID: 29882797
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic therapy of cancer with histone deacetylase inhibitors.
Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
[TBL] [Abstract][Full Text] [Related]
12. Histone deacetylase inhibitors modulate the transcriptional regulation of guanylyl cyclase/natriuretic peptide receptor-a gene: interactive roles of modified histones, histone acetyltransferase, p300, AND Sp1.
Kumar P; Tripathi S; Pandey KN
J Biol Chem; 2014 Mar; 289(10):6991-7002. PubMed ID: 24451378
[TBL] [Abstract][Full Text] [Related]
13. Tissue transglutaminase (TG2) is involved in the resistance of cancer cells to the histone deacetylase (HDAC) inhibitor vorinostat.
Carbone C; Di Gennaro E; Piro G; Milone MR; Pucci B; Caraglia M; Budillon A
Amino Acids; 2017 Mar; 49(3):517-528. PubMed ID: 27761756
[TBL] [Abstract][Full Text] [Related]
14. Molecular and biologic analysis of histone deacetylase inhibitors with diverse specificities.
Newbold A; Matthews GM; Bots M; Cluse LA; Clarke CJ; Banks KM; Cullinane C; Bolden JE; Christiansen AJ; Dickins RA; Miccolo C; Chiocca S; Kral AM; Ozerova ND; Miller TA; Methot JL; Richon VM; Secrist JP; Minucci S; Johnstone RW
Mol Cancer Ther; 2013 Dec; 12(12):2709-21. PubMed ID: 24092806
[TBL] [Abstract][Full Text] [Related]
15. HDACi--going through the mechanisms.
Wanczyk M; Roszczenko K; Marcinkiewicz K; Bojarczuk K; Kowara M; Winiarska M
Front Biosci (Landmark Ed); 2011 Jan; 16(1):340-59. PubMed ID: 21196174
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation.
Richon VM; Sandhoff TW; Rifkind RA; Marks PA
Proc Natl Acad Sci U S A; 2000 Aug; 97(18):10014-9. PubMed ID: 10954755
[TBL] [Abstract][Full Text] [Related]
17. Human endometrial cytodifferentiation by histone deacetylase inhibitors.
Uchida H; Maruyama T; Nagashima T; Ono M; Masuda H; Arase T; Sugiura I; Onouchi M; Kajitani T; Asada H; Yoshimura Y
Hum Cell; 2006 Feb; 19(1):38-42. PubMed ID: 16643606
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase inhibitors potentiate photodynamic therapy in colon cancer cells marked by chromatin-mediated epigenetic regulation of
Halaburková A; Jendželovský R; Kovaľ J; Herceg Z; Fedoročko P; Ghantous A
Clin Epigenetics; 2017; 9():62. PubMed ID: 28603560
[TBL] [Abstract][Full Text] [Related]
19. HDAC inhibition results in widespread alteration of the histone acetylation landscape and BRD4 targeting to gene bodies.
Slaughter MJ; Shanle EK; Khan A; Chua KF; Hong T; Boxer LD; Allis CD; Josefowicz SZ; Garcia BA; Rothbart SB; Strahl BD; Davis IJ
Cell Rep; 2021 Jan; 34(3):108638. PubMed ID: 33472068
[TBL] [Abstract][Full Text] [Related]
20. CG0006, a novel histone deacetylase inhibitor, induces breast cancer cell death via histone-acetylation and chaperone-disrupting pathways independent of ER status.
Kim HM; Kim CS; Lee JH; Jang SJ; Hwang JJ; Ro S; Hyun YL; Choi J
Breast Cancer Res Treat; 2011 Nov; 130(2):365-75. PubMed ID: 21184271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]